Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CSL ( (AU:CSL) ) just unveiled an announcement.
CSL Limited has announced an update regarding its ongoing on-market buy-back program, which involves the repurchase of its ordinary fully paid securities. As of November 19, 2025, the company has bought back a total of 2,079,952 securities, with an additional 59,477 securities repurchased on the previous day. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and enhance shareholder value.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$225.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is a global biotechnology company that specializes in the development and delivery of innovative medicines. The company focuses on providing life-saving therapies for people with rare and serious diseases, including blood disorders, immunodeficiencies, and other medical conditions.
Average Trading Volume: 1,382,208
Technical Sentiment Signal: Sell
Current Market Cap: A$88.21B
Learn more about CSL stock on TipRanks’ Stock Analysis page.